Trial Profile

A prospective, open-label, single-arm, multicenter clinical study of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in ADVANCE-CIDP 1 trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2025 Results (n=20) assessing IVIG 10% as a rescue treatment for patients relapsing during the ADVANCE-CIDP 1 trial, published in the European Journal of Neurology.
01 Feb 2024 New trial record
29 Jan 2024 According to a Takeda media release, company announced that the US FDA has approved GAMMAGARD LIQUID therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) based on results from ADVANCE-CIDP 2 trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com